Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jared A Leff

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2011
The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluationBruce R Schackman, Jared A Leff, Michael Botsko, et al.
Drug and Alcohol Dependence|August 11, 2020
Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trialAli Jalali, Danielle A Ryan, Philip J Jeng, et al.
AIDS (London, England)|March 28, 2014
The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patientsBenjamin P Linas, Devra M Barter, Jared A Leff, et al.
Addiction Science & Clinical Practice|November 15, 2018
Closing the gaps in opioid use disorder research, policy and practice: conference proceedingsMatthew A Miclette, Jared A Leff, Isabella Cuan, et al.
Substance Abuse Treatment, Prevention, and Policy|April 9, 2021
Harmonizing healthcare and other resource measures for evaluating economic costs in substance use disorder researchMichelle A Papp, Jared A Leff, Sean M Murphy, et al.
Drug and Alcohol Dependence|September 14, 2012
The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trialBruce R Schackman, Lisa R Metsch, Grant N Colfax, et al.
Open Forum Infectious Diseases|May 9, 2017
Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1Benjamin P Linas, Jake R Morgan, Mai T Pho, et al.
BMC Health Services Research|March 25, 2017
The structural and health policy environment for delivering integrated HIV and substance use disorder treatments in Puerto RicoJared A Leff, Diana Hernández, Paul A Teixeira, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care SettingsSabrina A Assoumou, Abriana Tasillo, Jared A Leff, et al.
Annals of Internal Medicine|March 31, 2015
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infectionBenjamin P Linas, Devra M Barter, Jake R Morgan, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2011
The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluationBruce R Schackman, Jared A Leff, Michael Botsko, et al.
Drug and Alcohol Dependence|August 11, 2020
Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trialAli Jalali, Danielle A Ryan, Philip J Jeng, et al.
AIDS (London, England)|March 28, 2014
The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patientsBenjamin P Linas, Devra M Barter, Jared A Leff, et al.
Addiction Science & Clinical Practice|November 15, 2018
Closing the gaps in opioid use disorder research, policy and practice: conference proceedingsMatthew A Miclette, Jared A Leff, Isabella Cuan, et al.
Substance Abuse Treatment, Prevention, and Policy|April 9, 2021
Harmonizing healthcare and other resource measures for evaluating economic costs in substance use disorder researchMichelle A Papp, Jared A Leff, Sean M Murphy, et al.
Drug and Alcohol Dependence|September 14, 2012
The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trialBruce R Schackman, Lisa R Metsch, Grant N Colfax, et al.
Open Forum Infectious Diseases|May 9, 2017
Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1Benjamin P Linas, Jake R Morgan, Mai T Pho, et al.
BMC Health Services Research|March 25, 2017
The structural and health policy environment for delivering integrated HIV and substance use disorder treatments in Puerto RicoJared A Leff, Diana Hernández, Paul A Teixeira, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care SettingsSabrina A Assoumou, Abriana Tasillo, Jared A Leff, et al.
Annals of Internal Medicine|March 31, 2015
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infectionBenjamin P Linas, Devra M Barter, Jake R Morgan, et al.
Pageof 4